CJC-1295 is a synthetic peptide that falls under the category of Growth Hormone Releasing Hormones (GHRH). It is designed to enhance the release of growth hormone (GH) from the pituitary gland. Its structure allows for a modification that increases the half-life of the peptide, making it more effective over a longer period compared to its natural counterpart, GHRH. This is achieved through a process known as drug affinity complex (DAC) technology, which involves the addition of DAC to the peptide chain, thereby slowing the rate of degradation.
The primary mechanism of action of CJC-1295 involves binding to the growth hormone-releasing hormone receptor (GHRHR) on the pituitary gland. This interaction stimulates the pituitary gland to release GH into the bloodstream. Increased levels of GH can lead to enhanced muscle growth, improved recovery times, and a boost in metabolism. These effects make CJC-1295 of interest not only in the context of promoting physical performance and muscle growth but also in the potential for anti-aging effects, as growth hormone plays a key role in the maintenance and repair of tissues.
CJC-1295 is often used in research settings and by bodybuilders or athletes seeking to enhance their physical performance and recovery. Its extended half-life, due to the DAC technology, means that it does not require daily administration to maintain elevated levels of growth hormone, making it more convenient than other GHRH analogs.
It's important to note that the use of peptides like CJC-1295 should be approached with caution and undertaken only under medical supervision, as the manipulation of hormone levels in the body can have significant and sometimes unpredictable effects. The legal status and approval for use of CJC-1295 may vary by country and it is primarily available for research purposes.